Business Context and Reporting Period
Company: Tempest Therapeutics, Inc. (TPST)
Filing Type: Form 8-K (Current Report)
Date of Report: March 19, 2024
Reporting Period: Year ended December 31, 2023
This filing serves to announce the Company's financial results for the full year 2023 and provide a business update. The detailed results are contained in a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the 8-K filing and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the source text provided.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms that a press release detailing the year-end 2023 results and business highlights was issued.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release titled "Tempest Reports Year End 2023 Financial Results and Provides Business Update."
Legal Disclaimer: The information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific revenue, net loss, and cash position figures for 2023.
- Verify the Company's cash runway and burn rate as disclosed in the full financial statements.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the business update.
- Confirm the status of the Series A Junior Participating Preferred Purchase Rights listed in the filing.